-
4 weeks ago | 
sicklecellanemianews.com | Marisa Wexler |Sylvia Amuta |Mary Chapman |Mary Shaniqua
This month, the University of Tennessee Health Science Center College of Nursing is hosting a conference that aims to educate primary care doctors about sickle cell disease (SCD). The Sickle Cell Disease Comprehensive Management for Health Care Providers conference is being funded by a two-year, $364,502 grant from the U.S. Department of Agriculture, awarded in 2023.
-
2 months ago | 
sicklecellanemianews.com | Steve Bryson |Andrea Lobo |Mary Chapman
Immvention Therapeutix has partnered with Novo Nordisk to develop oral treatments for people with sickle cell disease (SCD) and other chronic conditions. The U.S.-based Immvention called the deal “a strategic collaboration and license agreement” in a company press release. “We are excited to partner with Novo Nordisk,” said Anil Goyal, PhD, CEO and cofounder of Immvention.
-
Jan 14, 2025 | 
huntingtonsdiseasenews.com | Marisa Wexler |Steve Bryson |Mary Chapman
Abnormalities in a protein called TDP-43, which is known to play a key role in the development of amyotrophic lateral sclerosis (ALS), may also underly Huntington’s disease, a study found, meaning strategies being explored as treatments for ALS might also be useful for treating Huntington’s.
-
Jan 10, 2025 | 
sicklecellanemianews.com | Mary Shaniqua |Esteban Cerezo |Sylvia Amuta |Mary Chapman
Living with sickle cell disease comes with a heavy cost. Much of your time is spent seeking to understand your body, how the condition impacts you as a person, and then adjusting your lifestyle to maximize this knowledge. This is a never-ending process because life takes you through seasons, physically as you grow, but also emotionally and socially. All of these can affect the condition and, in turn, have an impact on your health outcomes.
-
Jan 10, 2025 | sicklecellanemianews.com | Mary Shaniqua |Esteban Cerezo |Sylvia Amuta |Mary Chapman
Living with sickle cell disease comes with a heavy cost. Much of your time is spent seeking to understand your body, how the condition impacts you as a person, and then adjusting your lifestyle to maximize this knowledge. This is a never-ending process because life takes you through seasons, physically as you grow, but also emotionally and socially. All of these can affect the condition and, in turn, have an impact on your health outcomes.
-
Nov 27, 2024 | 
sicklecellanemianews.com | Oluwatosin Adesoye |Mary Shaniqua |Mary Chapman |Marisa Wexler
Blood transfusions play a critical role in the management of sickle cell disease. They can help prevent and manage various complications as well as reduce disease severity. This lifesaving intervention has brought many sickle cell patients on the verge of death back to life — including me. Despite being diagnosed with sickle cell when I was just 1 year old, I didn’t receive my first blood transfusion until I was 22. I took pride in that, feeling I was a special sickle cell warrior.
-
Nov 19, 2024 | 
sicklecellanemianews.com | Marisa Wexler |Andrea Lobo |Steve Bryson |Mary Chapman
The Clinton Health Access Initiative (CHAI) is leading a project that aims to expand access to diagnostic tests and treatments for sickle cell disease (SCD). The project is being funded by a three-year, $8 million grant from Open Philanthropy, an advised fund of the Silicon Valley Community Foundation, the largest charitable foundation in Silicon Valley, a region of northern California known for its high-tech industries.
-
Nov 14, 2024 | 
sicklecellanemianews.com | Margarida Maia |Andrea Lobo |Marisa Wexler |Mary Chapman
It may be possible to collect nearly three times as many stem cells for gene therapy for sickle cell disease (SCD) with BioLineRx’s motixafortide than with standard plerixafor, and even more when it’s combined with natalizumab, a Phase 1 study shows.
-
Oct 31, 2024 | 
sicklecellanemianews.com | Margarida Maia |Andrea Lobo |Mary Shaniqua |Mary Chapman
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Kind Pharmaceuticals’ investigational oral small molecule AND017 to treat sickle cell disease (SCD). This designation is granted to potential treatments for rare diseases, or those affecting fewer than 200,000 people in the U.S. It provides incentives like tax credits for clinical trials, exemption from certain fees, and seven years of market exclusivity if an approval is ultimately granted.
-
Oct 8, 2024 | 
sicklecellanemianews.com | Patricia Inacio |Steve Bryson |Mary Chapman |Marisa Wexler
Mitem Pharma has acquired worldwide rights to Desferal (deferoxamine), a therapy commonly used to lower excessive and damaging iron levels induced by blood transfusions in people with sickle cell disease (SCD) or other anemias. The acquisition was reached in an agreement between Mitem and Novartis, which developed and initially marketed Desferal. Its terms were not disclosed.
